The panelist discussed the SALT scoring system, which divides the scalp into four regions — the frontal parietal scalp, bilateral preauricular and postauricular scalp, and posterior scalp — and evaluates the percentage of hair loss in each area to produce a composite score ranging from 0 to 100, with a score below 20 serving as the primary efficacy benchmark in JAK inhibitor clinical trials.
The expert clinician examined the multidisciplinary approach to alopecia areata care, with the board-certified dermatologist serving as the central coordinator, supported by pediatricians and family practice providers for early recognition and timely referral, dermatopathologists for cases requiring biopsy, and specialists in endocrinology, rheumatology, and psychiatry or psychology for management of associated comorbidities and psychosocial needs.
Arash Mostaghimi highlighted the scientific journey that led to Janus kinase (JAK) inhibitors becoming a treatment avenue for alopecia areata, beginning with a case report by Brett King in which a patient with psoriatic arthritis receiving tofacitinib experienced complete scalp hair regrowth despite also having AA.
The panelist examined the pivotal trial design for baricitinib, which enrolled patients with severe AA — defined as a Scalp Area and Hair Loss Tool (SALT) score greater than 50 — and demonstrated that approximately 30% of patients achieved a SALT score below 20 at 36 weeks on the 4 mg dose, with the 2 mg dose performing substantially lower.
Dr. Mostaghimi discussed the clinical trial data for deuruxolitinib, a JAK1/2 inhibitor dosed at 8 mg twice daily, which demonstrated a faster onset of action compared with baricitinib and ritlecitinib — achieving mid-30% Scalp Area and Hair Loss Tool (SALT) score less than 20 response rates at 24 weeks, approximately 3 months earlier than baricitinib at 36 weeks.
The expert dermatologist examined how patient-specific factors drive JAK inhibitor selection, with baricitinib favored for patients who prioritize an established long-term safety record, ritlecitinib preferred for adolescents aged 12 to 17 and patients with baseline dyslipidemia, and deuruxolitinib reserved for those seeking faster and more robust hair regrowth or who have not responded adequately to another JAK inhibitor.
